- Must have met the inclusion criteria for preceding double-blind study
- Must have received pregabalin or amitriptyline or placebo under double-blind
conditions under double-blind conditions at least during first 3 weeks if
double-blind treatment phase of preceding study.
- Patients cannot be included if they experienced a serious adverse event while
participating in preceding double-blind study, which was determined to be related to
the study medication.